Use of dipeptidyl peptidase IV inhibitors in the treatment...

Details Use of dipeptidyl peptidase IV inhibitors in the treatment... Use of dipeptidyl peptidase IV inhibitors in the treatment...

2008-05-06

2008-05-06

Kosar, Andrew D. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S017400, C514S018700, C514S019300, C530S300000, C530S329000, C530S330000, C530S331000, C530S332000

Reexamination Certificate

active

07368421

ABSTRACT:
The present invention provides a new use of DP IV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DP IV or DP IV-like enzymes, such as immune, autoimmune or central nervous system disorder selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5827898 (1998-10-01), Khandwala et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6011155 (2000-01-01), Villhauer
patent: 6107317 (2000-08-01), Villhauer
patent: 6110949 (2000-08-01), Villhauer
patent: 6124305 (2000-09-01), Villhauer
patent: 6172081 (2001-01-01), Damon
patent: 6201132 (2001-03-01), Jenkins et al.
patent: 6271231 (2001-08-01), Bergstrand et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6319893 (2001-11-01), Demuth et al.
patent: 6500804 (2002-12-01), Demuth et al.
patent: 6526083 (2003-02-01), Kneissl et al.
patent: 6548481 (2003-04-01), Demuth et al.
patent: 6586403 (2003-07-01), Mathison et al.
patent: 6605589 (2003-08-01), Uckun et al.
patent: 2001/0025023 (2001-09-01), Carr
patent: 2002/0165164 (2002-11-01), Demuth et al.
patent: 25 42 598 (1976-04-01), None
patent: 296 075 (1991-11-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-09-01), None
patent: 198 26 972 (1999-12-01), None
patent: 198 34 610 (2000-02-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 995 440 (2000-04-01), None
patent: PCT/EP00/08118 (2001-03-01), None
patent: 1 130 022 (2001-09-01), None
patent: 2 085 665 (1971-12-01), None
patent: 2 696 740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 01/09169 (2001-02-01), None
patent: WO 01/32624 (2001-05-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/74299 (2001-10-01), None
patent: WO 01/89569 (2001-11-01), None
patent: WO 01/94310 (2001-12-01), None
patent: WO 01/97808 (2001-12-01), None
patent: WO 2004/066931 (2001-12-01), None
patent: WO 02/20825 (2002-03-01), None
patent: WO 03/016335 (2003-02-01), None
Ba 't Hart, et al. Evaluating the validity of animal models for research into therapies for immune-based disorders. (2004) Drug Discovery Today, 9, 517-524.
A Sedo and R Malik. Dipeptidyl peptidase IV-like molecules: homologous protein or homologous activities? (2001) Biochmica et Biophysica Acta, 1550, 107-116.
W.S. Messer, “Vasopressin and Oxytocin”, web document updated Apr. 3, 2000; http://www.neurosci.pharm.utoledo.edu/MBC3320/Vasopressin.htm; 5 pages.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
D.E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
Ba 't Hart, et al. Drug Discovery Today (2004) 9, 517-524.
A Sedo and R Malik. Biochimica et Biophysica Acta (2001) 1550, 107-116.
I. De Meester, et al. Immunol. Today (1999) 20(8), pp. 367-375.
A. Steinbrecher, et al. Adv. Exp. Med. Biol. (2000) 477, pp. 145-153.
D. Reinhold, et al. Adv. Exp. Med. Biol. (2000) 477, pp. 155-160.
“Progress Continues Against Multiple Sclerosis.” Mercy Health System of Oklahoma. Mar. 2005, 4 pages, internet document <<http://www.mercyok.net/healthinfo/archive/050330.asp>>, accessed Oct. 10, 2006.
Campbell, I.W. New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and metformin: efficacy and inadequacy”. 3:33-51 (1990).
The Merck Index, 11thEdition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, p. 934.
The Merck Index, 12thEdition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, p. 1014.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 1619.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 36.
Chemical Abstracts, vol. 115. No. 15, Oct. 14, 1991 Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts, vol. 126, No. 2, Jan. 13, 1997 Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Chemical Abstracts, vol. 118, No. 25, Jun. 21, 1993 Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, Nov. 1992.
Arai et al: “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain” Chemical and Pharmaceutical Bulletin., Bd. 41, No. 9, 1993, pp. 1583-1588.
J. Lin et al.: “Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics” Proceedings of the National Academy of Sciences of USA, vol. 95, Nov. 1998, pp. 14020-14024.
Korom, S., et al “Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients”, Transplantation vol. 63, 1495—1500 No. 10 (1997).
Tanka, S., et al., “Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV”. Int. J. Immunopharmacol, vol. 19, No. 1 pp. 15-24, 1997.
Mentlein, R., et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”. Regul. Pept. 49, 133-144(1993).
Wetzl, W., et al., “Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes”. Neuropeptides, 31, 41-45 (1997).
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed inXenopus laevisoocytes”. J. Physiol. 504, 169-174 (1997).
Durinx, C.; et al.; “Reference Values for Plasma Dipeptidyl-Pepidase IV activity and their Associatin with Other Laboratory Parameters”. Clin Chem Lab Med 2001, February; 39 (2) : 155-9, 1 page.
Gossrau, R.; “Cytochemistry of Membrane Proteases”. Histochem J, Jul. 1985; 17 (7) :737-71, 1 page, Abstract only.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae”. Acta Histochem 1993, Dec. 1995 (2) :185-92, 1 page.
Heymann, E.; et al.

Affiliated with

Also associated with

Rating

Use of dipeptidyl peptidase IV inhibitors in the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of dipeptidyl peptidase IV inhibitors in the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of dipeptidyl peptidase IV inhibitors in the treatment... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2748748